H
Heinz Gisslinger
Researcher at University of Vienna
Publications - 143
Citations - 10744
Heinz Gisslinger is an academic researcher from University of Vienna. The author has contributed to research in topics: Multiple myeloma & Polycythemia vera. The author has an hindex of 41, co-authored 132 publications receiving 9774 citations. Previous affiliations of Heinz Gisslinger include Vienna General Hospital & Ruhr University Bochum.
Papers
More filters
Journal ArticleDOI
Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms
Thorsten Klampfl,Heinz Gisslinger,Ashot S. Harutyunyan,Harini Nivarthi,Elisa Rumi,Jelena D. Milosevic,Nicole C.C. Them,Tiina Berg,Bettina Gisslinger,Daniela Pietra,Doris Chen,Gregory I. Vladimer,Klaudia Bagienski,Chiara Milanesi,Ilaria Carola Casetti,Emanuela Sant'Antonio,Virginia Valeria Ferretti,Chiara Elena,Fiorella Schischlik,Ciara Cleary,Melanie Six,Martin Schalling,Andreas Schönegger,Christoph Bock,Luca Malcovati,Cristiana Pascutto,Giulio Superti-Furga,Mario Cazzola,Robert Kralovics +28 more
TL;DR: Most patients with essential thrombocythemia or primary myelofibrosis that was not associated with a JAK2 or MPL alteration carried a somatic mutation in CALR, and patients with mutated CALR had a lower risk ofThrombosis and longer overall survival than patients with mutations in J AK2.
Journal ArticleDOI
JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.
Claire N. Harrison,Jean-Jacques Kiladjian,Haifa Kathrin Al-Ali,Heinz Gisslinger,Roger J. Waltzman,Viktoriya Stalbovskaya,Mari McQuitty,Deborah S. Hunter,Richard S. Levy,Laurent Knoops,Francisco Cervantes,Alessandro M. Vannucchi,Tiziano Barbui,Giovanni Barosi +13 more
TL;DR: Continuous ruxolitinib therapy, as compared with the best available therapy, was associated with marked and durable reductions in splenomegaly and disease-related symptoms, improvements in role functioning and quality of life, and modest toxic effects.
Journal ArticleDOI
Efficacy and Safety of Low-Dose Aspirin in Polycythemia Vera
Raffaele Landolfi,Roberto Marchioli,Jack Kutti,Heinz Gisslinger,Gianni Tognoni,Carlo Patrono,Tiziano Barbui +6 more
TL;DR: Low-dose aspirin can safely prevent thrombotic complications in patients with polycythemia vera who have no contraindications to such treatment, and reduced the risk of the combined end point of nonf fatal myocardial infarction, nonfatal stroke, pulmonary embolism, major venous thromBosis, or death from cardiovascular causes.
Journal ArticleDOI
Vascular and Neoplastic Risk in a Large Cohort of Patients With Polycythemia Vera
Roberto Marchioli,Guido Finazzi,Raffaele Landolfi,Jack Kutti,Heinz Gisslinger,Carlo Patrono,Raphael Marilus,Ana Villegas,Gianni Tognoni,Tiziano Barbui +9 more
TL;DR: The persistently high mortality rate from hematologic malignancies characterizes the unmet therapeutic need of polycythemic patients and suggests a priority for future studies in this disease.
Journal ArticleDOI
Erythropoietin treatment of anemia associated with multiple myeloma.
TL;DR: It is concluded that recombinant human erythropoietin is a promising therapeutic tool for treating myeloma-associated anemia and its symptoms of anemia subsided, and they reported a heightened sense of well-being.